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ABSTRACT 
 Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy 
for upper gastrointestinal disorders, including GERD, dyspepsia, and PUD. The 
effectiveness of PPIs has led to overutilization in multiple treatment areas, 
exposing patients to an increasing number of potential risks. The overutilization of 
PPIs in ambulatory care settings is often a result of failure to re-evaluate the need 
for continuation of therapy. Despite clear indications for long-term PPI therapy, 
many patients continue to over-utilise these medications inappropriately without 
re-evaluation. A potential consequence of prolonged PPI therapy is the potential 
for long term hyper-gastrinemia and parietal cell hypertrophy.  
 PPIs are frequently used in patients who do not meet the criteria for 
appropriate use and where less powerful, cheaper agents would be effective for 
the treatment of symptoms. Even though the indications for PPI prescription are 
well defined by U.S FDA, these indications are often ignored. Reducing 
inappropriate prescribing of PPIs in the inpatient and outpatient settings can 
minimize potential for adverse events, and can also help in controlling cost 
expenditure.  
 The objective of the study is to determine the appropriateness and compare 
the cost of prescriptions of PPIs in the selected study population as per the 
inclusion criteria. The prospective observational study was conducted. The data 
was collected during regular ward rounds and was analysed.  The appropriateness 
was analysed using the FDA guidelines. 
 A total of 209 patients were included in the study, their prescriptions were 
analysed to determine appropriateness. The study population was categorised 
under different risk groups based on the number of risks. The different risks in the 
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study population was found to be age, stress related profession, use of alcohol, 
smoking and chronic NSAID users. The patients were categorised into 4 main 
groups, i.e. no risk, moderate risk, high risk and very high risk categories. 
Majority of the patients 83 (39.71%) came under the moderate risk category, 
followed by 64 patients (30.62%) in the low risk category, 52 patients (24.88%) in 
the high risk category and 10 patients (4.79%) in the very high risk categories.  
 The total number of drugs prescribed for the study population was found to 
be 2024. A total of 285 (14.08%) antibiotics were prescribed, followed by 209 
(10.33%) PPIs, 155 (7.65%) anti-diabetics, 132 (6.32%) anti-hypertensives, 129 
(6.18%) NSAIDs, 115 (5.51%) anti-emetics and others. Among the 209 PPIs 
prescribed in the study population pantoprazole was the most frequently 
prescribed 144 (68.89%). Esomeprazole 46 (22.01%) comes next in line followed 
by rabeprazole 17 (8.13%) and omeprazole 2 (0.95%).  
 Appropriateness of prescription of PPIs in the study population was 
analysed using the FDA guidelines, out of 209 patients 115 (55.02%) were found 
to be appropriately prescribed with PPIs, which indicates there is recommended 
conditions as mentioned in guidelines and 94 (44.98%) prescriptions were found 
to be inappropriate, i.e., there was no necessary indication of PPI use as per the 
guidelines. The inappropriate prescriptions with PPIs were analysed and it was 
found that inappropriateness in prescriptions may be due to several reasons, i.e. 
wrong frequency, wrong dosage form, availability of alternative, prolonged 
duration of treatment, inappropriate indication and occurrence of adverse events. 
Majority of the inappropriate prescriptions involved pantoprazole followed by 
esomeprazole and rabeprazole.  
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The cost of treatment can be reduced in 94 patients who have been 
prescribed with PPIs inappropriately. Among these 94 patients, 71 patients were 
identified with H2RAs as an alternate drug instead of PPI by which the cost of 
treatment will be reduced. An unnecessary healthcare cost to the patient is a 
matter of concern and necessary action must be taken. 
 The results reveal that interventions made by the pharmacist avoided the 
inappropriate use of PPI at the study site. Most of the inappropriate prescriptions 
were consisting increased frequency of dosing and utilising PPIs for prophylactic 
use. Reducing PPI use will prevent the risk associated with PPIs and also reduce 
cost involved with its use. The need for PPI use in the individual patient must be 
evaluated by the pharmacist and if any possible alternatives are found to be 
effective the same can be reported to the physician. The regular monitoring of 
prescription of PPI by clinical pharmacist is the need of the hour. 
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INTRODUCTION 
 PUD is common among adults in modern society. It occurs due to imbalance 
between the aggressive and defensive factors1. Approximately 500,000 new cases 
are reported each year. A variety of psychosomatic, humoral and vascular 
derangements have been implicated and the importance of Helicobacter pylori (H. 
pylori) infection as a contributor to ulcer formation and recurrence has been 
recognized2. 
The physical morbidity associated with this disease justifies the continued 
interest in its epidemiology. Although the prevalence of PUD is decreasing in many 
communities, it still affects approximately 10% of adults at some point in their lives. 
The prevalence is seen to increase with age3. The male to female ratio for duodenal 
ulcer varies from 5:1 to 2:1, whereas that for gastric ulcer is 2:1 or less4. The 
incidence of PUD has fluctuated considerably in the past. The incidence varies with 
ulcer type, age, gender, and geographic location. The prevalence of PUD has shifted 
from predominance in men to nearly comparable prevalence in men and women. 
According to the latest World Health Organisation (WHO) published data in May 
2014, PUD deaths in India reached 85,487 or 0.96% of total deaths5.  
 Patients with PUD may present with a range of symptoms, from mild 
abdominal discomfort to perforation and bleeding. The risk factors for peptic ulcers 
include4: 
 H. pylori infection 
 Age greater than 65 years 
 Stress  
 High dose of non-steroidal anti-inflammatory drugs (NSAIDs) or more than 
 one NSAID (including aspirin) 
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 Short-term history of NSAID use (<1 month) 
 Hypersecretory condition 
 Smoking 
 Drinking alcohol 
 Although mortality rates from PUD are low, the high prevalence and the 
resulting pain, suffering and expense are very costly. The drugs which are 
commonly used for ulcer therapy are H2 receptor blockers, proton pump inhibitors 
(PPIs), ulcer protective agents, antacids and anti-H.pylori drugs5.  
1. Reduction of gastric acid secretion 
(a) H2 receptor antagonists (H2RAs) : Ranitidine, Famotidine 
(b) PPIs : Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, 
 Esomeprazole 
(c) Anticholinergics : Pirenzepine, Propantheline 
(d) Prostaglandin analogue : Misoprostol 
2. Neutralization of gastric acid (Antacids) 
(a) Systemic : Sodium bicarbonate, Sodium citrate 
(b) Non-systemic : Magnesium hydroxide, Magnesium trisilicate, Aluminium 
 hydroxide gel, Magaldrate, Calcium carbonate 
3. Ulcer protectives : Sucralfate, Colloidal bismuth subcitrate 
4. Anti-H. pylori drugs : Amoxicllin, Clarithromycin, Metronidazole, 
 Tinidazole, Tetracycline4 
 Anti-ulcer drugs are mainly used for the treatment of PUD, 
gastroesophageal reflux disorder (GERD), gastritis and Zollinger-Ellison syndrome 
(ZES). The main goals of anti-ulcer therapy include relief from pain, promotion of 
ulcer healing, prevention of complications and prevention of relapse. Various 
strategies to maintain the disease in remission are continuous or on demand – 
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intermittent H2RAs or PPI, maintenance sucralfate or antacid treatment. Out of this 
continuous maintenance H2RAs or PPI therapy is regarded as the most effective and 
convenient6.  
The best approach, however, is to identify and treat H. pylori positive cases. 
Long term acid suppressive therapy would then be needed only in H. pylori negative 
cases4. 
PROTON PUMP INHIBITORS (PPIs) 
 PPIs signify a revolutionary development in gastroenterology. These drugs 
irreversibly inhibit the gastric H+, K+ ATPase pump and decrease both basal and 
stimulated gastric acid production. PPIs are successful and cost-effective for the 
treatment of severe gastro esophageal reflux disorder (GERD) and other acid-
related disorders. Prescriptions for PPIs have increased extremely over the last 
decade6,7.  
   
 PPIs have emerged as the chief treatment for GERD and peptic ulcer disease 
due to their effectiveness and low toxicity in treating these conditions6,8. PPIs are 
first choice in the treatment of GERD and peptic ulcers for a period of 4-8 weeks. 
In combination with antibiotics, they are used for abolition of H. pylori infection. 
After abolition for symptomatic H. pylori infection, continuation of PPI is usually 
not necessary except when there is another indication. PPIs are also indicated as a 
simultaneous medication to prevent NSAID and aspirin related ulcers in high-risk 
patients9,10.  
  
The available PPIs (such as, pantoprazole, rabeprazole etc.) are equal in 
effectiveness and safety but differ in cost. PPIs certainly offer an improvement in 
the treatment of common and important gastrointestinal diseases. They are effective 
in the cure or prevention of peptic acid disorders and in the management of GERD, 
esophagitis, gastric ulcer, bleeding peptic ulcer, eradication of H. pylori, dyspepsia, 
ZES and prevention of gastrointestinal (GI) toxicity induced by NSAIDs11,12.  
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PROBLEMS DUE TO PPI OVERUSE 
Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy 
for upper gastrointestinal disorders, including GERD, dyspepsia, and PUD. The 
effectiveness of PPIs has led to overutilization in multiple treatment areas, exposing 
patients to an increasing number of potential risks. The overutilization of PPIs in 
ambulatory care settings is often a result of failure to re-evaluate the need for 
continuation of therapy. PPI overutilization in the inpatient setting is often a result 
of inappropriate stress ulcer prophylaxis (SUP) in non-intensive care unit patients, 
and failure to discontinue SUP prior to hospital discharge13.   
 Despite clear indications for long-term PPI therapy, many patients continue 
to over-utilise these medications inappropriately without re-evaluation. A potential 
consequence of prolonged PPI therapy is the potential for long term hyper-
gastrinemia and parietal cell hypertrophy11.  
The potential risks associated with long-term use include vitamin B12 
deficiency, spontaneous bacterial peritonitis in cirrhotic patients with ascites, 
increased community-acquired pneumonia, diarrhoea due to Clostridium difficile 
and gastroenteritis due to Campylobacter jejuni. Iron deficiency anemia has been 
reported in patients with atrophic gastritis or gastric resection. There currently is no 
data demonstrating the development of iron deficiency anemia in normal subjects 
on PPI therapy7.  
PPIs also cause headaches and diarrhoea in more than 10% of cases. Studies 
have revealed that, people who use PPIs are up to 21% more probable to experience 
a heart attack9,11.  
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Risk of Fractures 
 The Food and Drug Administration (FDA) requires that labeling for PPIs 
include safety information about a possible increased risk of fractures of the hip, 
wrist, and spine. This requirement is based on an FDA review of several 
epidemiological studies with findings indicating that patients who may bear the 
highest risk for these fractures received a high dose of a PPI or had PPI therapy 
lasting longer than one year. The majority of these studies included individuals 50 
years old or older5. 
Risk of Hypomagnesemia  
 In March 2011, the FDA published a Drug Safety Communication to inform 
consumers and health care professionals that long-term use of PPIs can cause 
hypomagnesemia. In 25% of patients, magnesium supplementation was not 
sufficient to correct PPI-induced hypomagnesemia; rather, PPI therapy had to be 
discontinued. The FDA recommends obtaining a serum magnesium level prior to 
initiation of therapy if a patient is to be on prolonged treatment5.  
Risk of Clostridium difficile-Associated Diarrhea (CDAD) 
 On February 8, 2012, the FDA published a Drug Safety Communication to 
inform patients and health care professionals that PPIs may be associated with an 
increased risk of CDAD. Symptoms of CDAD include abdominal pain, fever, and 
watery stools. Patients who take a PPI and develop diarrhoea that does not improve 
should be evaluated for CDAD. Patients with advanced age, certain chronic medical 
conditions, and patients taking broad spectrum antibiotics are at greatest risk for 
developing CDAD. The FDA recommends using the lowest dose and shortest 
duration of PPI5.  
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 PPIs are frequently used in patients who do not meet the criteria for 
appropriate use and where less powerful, cheaper agents would be effective for the 
treatment of symptoms. Although there is evidence about superiority of the PPI over 
H2 receptor blockers and others drugs for the treatment of GERD or peptic ulcer, 
due to their stronger and longer action, other drugs could often be an effective and 
safe alternative for many patients10,11. Even though the indications for PPI 
prescription are well defined by U.S Food and Drug Administration (FDA), these 
indications are often ignored5.  
FDA Approved Indications for Proton Pump Inhibitors in Adults5 
The FDA-approved indications for use include: 
1. Healing of erosive esophagitis (EE) 
2. Maintenance of healed EE 
3. Treatment of GERD 
4. Risk reduction for gastric ulcer (GU) associated with NSAIDs 
5. H. pylori eradication to reduce the risk of duodenal ulcer (DU) recurrence, 
 in combination with antibiotics 
6. Pathological hypersecretory conditions, including ZES 
7. Short-term treatment and maintenance of DUs 
 The FDA approved indications and recommended dosing for each 
indication is given in Table 1. 
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ROLE OF PHARMACIST IN APPROPRIATE DRUG USE 
 
Table 1: Proton Pump Inhibitors: U.S FDA-Approved Indications and 
Dosages for Use in Adults5 
Indication Treatment 
DU 
Short-term:-  Lansoprazole - 15 mg O.D for 4 weeks 
Omeprazole -  20 mg O.D 
Rabeprazole - 20 mg O.D for 4 weeks 
Maintenance:- Lansoprazole - 15 mg O.D 
H.pylori 
eradication 
Esomeprazole - 40 mg O.D, amoxicillin 1000 mg and 
clarithromycin 500 mg B.D for 10 days 
Lansoprazole - 30 mg, amoxicillin 1000 mg and 
clarithromycin 500 mg B.D for 10 or 14 days 
Omeprazole - 20 mg, amoxicillin 1000 mg and clarithromycin 
500 mg B.D for 10 days 
Rabeprazole - 20 mg, amoxicillin 1000 mg and clarithromycin 
500 mg B.D for 7 days 
EE 
Healing:- Esomeprazole - 20 mg or 40 mg O.D for 4 to 8 
weeks 
Lansoprazole - 30 mg O.D for 8 weeks 
Omeprazole - 20 mg O.D for 4 to 8 weeks 
Pantoprazole - 40 mg O.D for 8 weeks 
Maintenance:- Esomeprazole - 20 mg O.D 
Lansoprazole - 15 mg O.D 
Omeprazole - 20 mg O.D 
Pantoprazole - 40 mg O.D 
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Indication Treatment 
GERD 
Healing:- Rabeprazole - 20 mg O.D for 4 to 8 weeks 
Maintenance:- Rabeprazole - 20 mg O.D 
Symptomatic:- Esomeprazole - 20 mg O.D for 4 weeks 
Lansoprazole - 15 mg O.D for 8 weeks 
Omeprazole - 20 mg O.D for 4 weeks 
Rabeprazole - 20 mg O.D for 4 weeks 
GU 
Short-term:- Lansoprazole - 30 mg  O.D for 8 weeks 
Omeprazole - 40 mg  O.D for 4 to 8 weeks 
Healing (NSAID associated):- Lansoprazole - 30 mg O.D for 
8 weeks 
Risk reduction (NSAID associated):- 
Esomeprazole - 20 mg or 40 mg  O.D for 6 months 
Lansoprazole - 15 mg O.D for 12 weeks 
Heartburn 
OTC Treatment:- Lansoprazole - 15 mg  O.D for 14 days 
Omeprazole - 20 mg  O.D  for 14 days 
Hypersecretory 
Conditions 
Esomeprazole - 40 mg B.D 
Lansoprazole - 60 mg  O.D 
Omeprazole - 60 mg  O.D 
Pantoprazole - 40 mg B.D 
Rabeprazole - 60 mg  O.D 
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“Appropriateness” has been described as “the next frontier” in the 
development of health care. Appropriateness is a complex issue with different 
dimensions and definitions and these differ between countries. However, most 
definitions of appropriateness address a number of key requirements such as; care 
is effective, efficient and consistent with the ethical principles and preferences of 
the relevant individual, community or society. The priorities given to each of these 
dimensions vary in different populations. Ethical values play a central role in 
determining the priorities given to components of appropriateness14.  
 The goal of health services in general is to provide effective care to patients 
who benefit from it in a manner that is acceptable to the patient and the health care 
provider, at a cost that is acceptable. A number of strategies are now available to 
improve appropriateness. The development and use of clinical practice guidelines 
have been demonstrated to improve the appropriateness of care. Guidelines can be 
used to shape decisions about access, costs of care and coverage of services. 
Numerous government agencies and health-related organizations now develop 
evidence-based clinical practice guidelines14. 
 The role of pharmacists has been proven to improve many outcomes 
regarding patient health, including patient safety, disease and drug therapy 
management, healthcare costs, medication adherence and quality of life15. 
Pharmacists play a unique role in improving the appropriate use of PPIs within the 
hospital setting. Responsibilities of the pharmacist are the following16,17: 
 Restrict administration of PPIs to patients with appropriate indications as 
per guidelines within both the critical care and general medicine setting and 
thus help in preventing overutilization of PPIs. 
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 Inform prescribers about PPI strength abnormalities and practice guidelines 
 available to select most appropriate therapy for individual patient. 
 Encourage prescribers to make cost effective choice of PPIs that are 
 clinically appropriate. 
 Notify prescribers of PPI safety alerts and clinical updates.  
 Enhance quality of patient care and determine opportunities for 
 improvement in care provided. 
 Identify adherence and non-adherence with guidelines in prescribing. 
 Identify prescription pattern.  
 Identify potential prescription related problems such as drug-drug 
 interactions, under or overdosing and inappropriate therapy17. 
  The initiation and the continuous use of PPIs without correct indications 
will result in severe health conditions and subsequently significant costs. 
Administration of needless medication can also cause adverse effects and 
pharmacological interactions. Reducing inappropriate prescribing of PPIs in the 
inpatient and outpatient settings can minimize potential for adverse events, and can 
also help in controlling cost expenditure. 
 Literature Review 
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LITERATURE REVIEW 
 Anton P et al 201618 did a nationwide drug utilization study on the use of 
proton pump inhibitors among adults. The prevalence of PPI use increased fourfold 
during the study period. The study concluded that the use of PPIs is extensive and 
increasing rapidly, especially among the elderly. 
 
 Krishna K J et al 201619 carried out a prospective observational study on 
prescribing pattern of acid suppressant drugs in current clinical practice. This study 
found overuse and underuse of acid suppressant drugs in the study site. The study 
highlighted the need for a local protocol for rational use of these agents in current 
clinical practice. 
 
 Blesson M et al 201520 conducted a study on assessment of appropriateness 
in the usage of proton pump inhibitors in a tertiary care teaching hospital. The study 
concluded inappropriate prescription of PPIs without valid indications is prevalent 
among physicians in the healthcare system. Prescribers must be well conscious 
regarding usage of PPIs and selection of PPI must be done wisely and should be 
prescribed to the patients only if indicated. 
 
 Minh T H et al 201521 studied about acid suppressive therapy for stress 
ulcer prophylaxis in non-critically ill patients. This literature discourages the use of 
acid suppressive therapy (AST) for stress ulcer prophylaxis (SUP) in non-critically 
ill patients. This study came to the conclusion that a large percentage of non-
critically ill patients were given AST during their hospital stay; 88.5% of these 
medications were given inappropriately to patients who were at extremely low risk 
of gastrointestinal bleeding. 
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 Nirajan K et al 201522 conducted a study on proton pump inhibitors in 
general medicine unit of a tertiary care teaching hospital. Appropriate use of PPIs 
was found to be 76.93% whereas the inappropriate use was found to be 23.07%. 
The study recommended use of PPI only when there is documented evidence of a 
GI disorder that cannot be treated with an H2-receptor antagonist and where a PPI 
use is clinically justified.  
 
 Nousheen et al 201423 studied on the rationality of use of proton pump 
inhibitors in general practice. The incidence of improper use of PPIs varies from 
40-70%. The study suggested that awareness should be created among the clinicians 
in the hospital so that appropriate prescription of PPIs will improve.  
 
 Shobha C et al 201424 performed a prospective assessment of prescribing 
pattern of intravenous proton pump inhibitors in an Indian hospital. This study 
revealed significant inappropriateness of PPI administration with particular 
reference to indication to use, duration of therapy, and changeover of therapy in an 
Indian tertiary-care teaching hospital.  
 
 Biswa M P et al 201425 studied on attitude and knowledge of Indian 
emergency care residents towards use of proton pump inhibitors. In conclusion the 
study stated that emergency care residents in India tend to overuse PPIs in a manner 
similar to their counterparts in developed countries. Specific measures may be 
helpful in preventing such practices. 
 
 Syed H A N et al 201426 performed a study on increasing use of proton pump 
inhibitors in Karachi. The results suggested that PPIs are over prescribed in primary 
and secondary care setting. There is scope towards more careful and cost-effective 
PPI prescribing which can improve adherence to evidence based practice and reduce 
the long term adverse effects of PPIs. 
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 Jessica F et al 201327 conducted a study on the potential influence of 
various initiatives to improve rational prescribing for PPIs. A retrospective 
observational study was conducted for assessing the influence of multiple initiatives 
on utilization and expenditure of the PPIs was carried out. Utilization was measured 
in terms of defined daily doses (DDDs) and DDDs/thousand inhabitants per day. 
The study stated that multiple reforms influenced utilization patterns and 
expenditure for the PPIs. 
 
 Heidelbaugh J J et al 201228 performed a review on proton pump inhibitors 
overutilization and the risks involved in overusage. This study concluded that 
prescription of PPI therapy in practice can be guided by several general principles 
to minimise potential risks. The study recommends that in patients with appropriate 
indications for PPI therapy, the lowest effective dose should always be prescribed. 
 
 Wesam F et al 201229 performed a prospective study on prescription 
patterns of PPIs for prophylaxis of stress-related mucosal disease in patients 
admitted to the intensive care unit. This study concluded that stress ulcer 
prophylaxis administration was inconsistent and includes both underutilization and 
overutilization. Educating physicians and implementing hospital protocols is 
important to improve PPI prescribing patterns. 
 
 Pasina L et al 201130 evaluated the prevalence and appropriateness of drug 
prescriptions for peptic ulcer and gastro-esophageal reflux disease in hospitalized 
elderly. The study concluded that prevalence of inappropriate prescription of drugs 
for peptic ulcer or GERD remained almost the same at admission and discharge. 
Inappropriate use of these drugs is related to the concomitant use of other drugs. 
Careful assessment of clinical conditions and stricter adherence to evidence-based 
guidelines are essential for a rational and cost-effective use of drugs for peptic ulcer 
or GERD.  
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 Soumana C N et al 201031 conducted a study on clinical and cost impact of 
intravenous proton pump inhibitor use in non-ICU patients. Updated guidelines 
were used to assess the appropriateness of the indication and route of 
administration. This study highlights the over-utilization of IV PPIs in non-
intensive care unit patients. Restriction of IV PPI use for justified indications and 
route of administration is recommended. 
 
 Elena R et al 201032 performed a study on overuse of PPIs in patients at 
admission, during hospitalisation, and at discharge in a tertiary Spanish hospital. 
The results of this study indicated that there was a very high frequency of overuse 
of PPIs in inpatients and outpatients.  
 
 Craig D G N et al 201033 carried out a prospective study on inappropriate 
utilization of intravenous proton pump inhibitors in hospital practice. This study 
suggested that the majority of IV PPI prescriptions in hospital were inappropriate. 
Improving prescribing awareness through education of junior medical staff could 
reduce inappropriate IV PPI use. 
 
 Jacob G H et al 200934 retrospectively evaluated the use of intravenous 
proton pump inhibitors in a teaching hospital. Indications for use were compared 
with current established guidelines to determine appropriate usage. The conclusion 
of the study stated that intravenous PPI prescribing habits in the study  
site were poor.  
 
 Nadia B et al 200935 carried out a study on the prescribing of PPIs and 
histamine-2 receptor antagonists (H2RAs) for defined gastrointestinal disorders. 
The study concluded that prescribing of H2RAs decreased, whereas the prescribing 
of PPIs increased.  
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 Ahmed Y M 200736 performed an observational study on improper use of 
ASDs in a tertiary care teaching hospital. The main objective was to evaluate the 
improper use of pantoprazole and ranitidine, and to identify the associated factors 
for misuse of these two drugs. Improper use of the drugs decreased as duration of 
hospital stay lengthened. Improper use of ASDs was observed in 43% of the 
patients. Based on the results of this study, correct measures need to be implemented 
in order reduce the misuse of ASDs.  
 
 Susan J S et al 200537 studied on collaboratively designed practice 
guidelines to promote appropriate use of intravenous PPIs. Patients initiated on IV 
pantoprazole therapy were evaluated prospectively for appropriateness of therapy. 
Pharmacists assessed clinical use, dosing strategy, administration route, and 
prescribing patterns. Evaluation of institutional pantoprazole utilization revealed 
usage extending beyond indications with proven efficacy. Pharmacists and 
physicians together developed evidence-based practice guidelines; adherence to 
these guidelines showed a 50% improvement. 
 
 Saad A Z M et al 200538 conducted a survey on proton pump inhibitors 
prescribing in an Irish general hospital. The results suggested that PPIs were over 
prescribed in hospital practice, and there is scope to improve the quality and cost-
effectiveness of PPI prescribing. 
 
 Jones M I et al 200139 did a study on PPI prescribing by general practitioner 
(GP). The objective was to compare GPs’ usage of different PPIs and evaluate how 
GPs’ prescribing changes following introduction of a cheaper competitor. It was 
reported that use of new PPIs increased from 6 to 24%. The wide variation in PPI 
prescribing suggests that there is scope for improvement in the quality and cost of 
PPI prescribing. 
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SCOPE OF THE STUDY 
 PPI overuse is widespread in both primary and secondary care. Concerns 
have been raised about the increasing costs related with prescription of these drugs 
as they are frequently prescribed. Studies from the US, Australia and Europe have 
confirmed overuse of PPIs in hospitalized patients and in primary care5,9. The 
suitability or appropriateness of PPI prescription is as low as 19%. PPIs are being 
used indiscriminately in both the intensive and non-intensive care settings. This is 
due to poor implementation and low compliance with the guidelines5.  
 One important factor for the widespread use of PPI is the administration of 
a PPI medication during a patient’s hospitalization and its continuation in primary 
care without proper reason. The dramatic increase in PPI prescribing patterns over 
the past several years has raised key questions relating to their appropriate 
utilization. In addition, concerns have been raised related to the inappropriate use 
of the intravenous (IV) route of administration and to a lesser extent incorrect doses 
and length of therapy. Furthermore, often patients are inappropriately discharged 
on PPIs which could potentially increase the risk of pneumonia and CDAD and 
metabolic interactions with several other drugs. Many patients admitted to general 
medical wards are also routinely placed on these drugs when neither their admission 
nor the comorbid diagnoses support their use for either treatment or prophylaxis34,40. 
 Multiple variables should be taken into consideration before prescribing a 
proton pump inhibitor. These include the dosages, period of therapy and  how often 
patients receiving a proton pump inhibitor for gastro-esophageal reflux disease 
(GERD) were also being treated with other medications which are known to worsen 
or cause GERD39.   
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 The federal agency for healthcare research and quality reported that PPI 
should be used only in patients with severe PUD, ZES and in H. pylori cases. But 
generally PPIs are used inappropriately for all kinds of ulcer and prophylaxis of 
ulcer. The sudden withdrawal of PPI leads to rebound hypersecretion of acid by 
parietal cells which lead to further complications5. 
 A study reported that PPIs can increase susceptibility to infections by 
decreasing stomach acid13. Normal stomach acidity helps to protect against certain 
bacterial and viral infections. This natural phenomenon is blocked by the use of 
PPIs41. It is suspected that acid suppression results in insufficient elimination of 
pathogenic organisms. Therefore, it has been suggested that patients at higher risk 
of pneumonia should be prescribed PPIs only at lower doses and only when 
necessary5.  
 Inappropriate recommendation of PPIs is a matter of concern. PPIs have 
slight side effects and few noteworthy drug interactions, and they are generally 
harmless for long-term treatment. PPIs are a chief economic burden for the 
healthcare system in many countries. PPIs are frequently used in patients who do 
not meet the criteria for appropriate use or for indications where less powerful, 
cheaper agents would be effective for the treatment of symptoms. There is high 
prevalence of inappropriate use of PPIs42,43. 
 PPIs should be prescribed in accordance with evidence-based guidelines in 
order to keep down unnecessary costs and prevent adverse drug reactions, which 
are a particular concern in the elderly. Inappropriate prescriptions are a particular 
concern among elderly patients, who normally have multiple comorbidities, take 
many drugs and are at higher risk of adverse drug reactions. Closer evaluation of 
the underlying clinical conditions and prescribing patterns are therefore essential 
for a rational, cost-effective approach44. As the use of PPIs continues to rise, 
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appropriate prescribing of PPIs is important to reduce adverse events in patients. 
Even in patients with appropriate indications for PPI use, this drug class has been 
related to several adverse events and risks to patient health10.  
 The above evidences about the overuse of PPIs and the problems associated 
with overuse of PPIs insisted to perform a study on appropriate use of PPIs. Thus, 
the present study is an attempt to evaluate the appropriateness in the usage of PPIs 
in the study site and to signify the role of pharmacist in reducing the use of PPIs.  
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OBJECTIVES 
 
 To study the appropriateness of  prescription of proton pump inhibitors in 
 study site  
 To compare cost of prescription of proton pump inhibitors 
 To observe the prescription pattern of proton pump inhibitors 
 To assess the drug-drug interactions in the prescriptions 
 To assess implementation of guidelines in prescription  
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PLAN OF STUDY 
 
  The study was planned to be carried out for a period of ten months 
from November 2015 to August 2016. The proposed study has been designed to 
be conducted in the following 4 phases. 
Phase I 
 Selection of study site and department  
 Literature survey 
 Preparation of Protocol 
 Obtaining consent from the hospital authorities 
Phase II 
 Designing of structured data entry format 
 Data collection  
 Documentation of collected data using the data entry format 
Phase III 
 Analysis of prescription pattern of PPIs in the study site 
 Evaluation of the appropriateness in prescription of PPIs 
 Analysis of occurrence of drug interactions associated with PPIs in 
prescriptions  
 Interpretation and evaluation of the data 
 Phase IV 
 Preparation of the project report and submission to the study department 
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METHODOLOGY 
STUDY SITE 
The proposed study entitled “study on appropriateness and cost 
comparison of prescription of proton pump inhibitors in a tertiary care 
hospital” was conducted at a 750 bedded multi-specialty hospital at Coimbatore. 
The hospital is unique and well known for its services to people who come from 
various parts of the country. The institution excels in diverse specialties like 
General Medicine, General Surgery, Obstetrics, Gynecology, Pediatrics and 
Neonatology, Orthopedics, Psychiatry, Neurology, Radiology, Cardiology, 
Cardiothoracic surgery, Pulmonology and Critical Care, Gastroenterology, 
Urology, Nephrology, E.N.T, Ophthalmology, Oncology, Dental and 
Maxillofacial surgery, Anesthesiology, Laparoscopic surgery, Physical Medicine 
and Rehabilitation, Diabetology and Surgical Gastro Enterology. The hospital has 
well-staffed Pharmacy and a Drug Information Centre.  
 The hospital is well equipped with the modern diagnostic facilities like 
somatum sensation (CT scan), MRI scan, Ultrasound Sonography, Digital 
Subtraction Angiography, PET scan, ECG, Treadmill, Colour Doppler etc. The 
hospital also has twelve well equipped hi-tech operation theatres, Intensive Care 
Unit, Intensive Cardiac Care Unit, Intensive Pulmonary Care Unit, Neonatal 
Intensive Care Unit, Catheterization laboratory performing diagnostic cardiac 
catheterization, Balloon Valvuloplasty, Coronary stenting, Kidney transplantation 
unit with Haemodialysis machines, assisted Reproductive Technology Centre, 24 
hour working microbiological and pathological services, round the clock casualty 
and pharmacy services. 
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DEPARTMENT SELECTED FOR STUDY 
The department selected for the study is the department of General 
Medicine. The department of General Medicine was selected after the pilot study 
which revealed more scope for the study in the department as the prescriptions of 
PPIs here are more. The Department of Pharmacy Practice provides services to the 
department of General Medicine and also has a good co-operation which added up 
reasons for selecting this department for the proposed study.  
STUDY DESIGN 
 Prospective observational study on appropriateness and cost comparison of 
prescription of PPIs 
STUDY PERIOD 
 Ten months, From November 2015 to August 2016 
CONSENT FROM THE HOSPITAL AUTHORITIES 
 Every project work carried out in the hospital by the Pharmacy Practice 
department students has to be  approved by the Dean of the hospital and should be 
informed to all physicians and other healthcare professionals of the hospital. A 
protocol of the study which included the objectives, methodology etc., was 
submitted to the Dean of the hospital. The authorization from the Dean was 
procured through his letter [SRH/EC.5-8/2016-17 dated 26 FEBRUARY 2016] 
Annexure 1. The study was conducted with the expert guidance of senior and 
junior physicians of the study department. The author was allowed to utilize the 
hospital facilities to follow up the cases in the selected department. All the health 
care professionals were well informed about the study program through the 
Dean’s official circular.  
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LITERATURE SURVEY  
 An extensive literature survey was done regarding the study on 
appropriateness and cost comparison of prescription of PPIs. The literatures 
pertaining to the study were collected from various sources such as:  
 Alimentary Pharmacology and Therapeutics 
 Annals of Pharmacotherapy 
 Archives of Internal Medicine 
 Canadian Family Physician 
 Canadian Pharmacists Journal 
 Digestive Diseases and Sciences 
 European Journal of Internal Medicine 
 Indian Journal of Pharmacology 
 Indian Journal of Pharmacy Practice 
 Indo American Journal of Pharmaceutical Research 
 International Journal of Clinical Practice 
 International Journal of Medical Research and Health Sciences 
 Journal of scientific and Innovative Research 
 Quarterly Journal of Medicine 
 Therapeutic Advances in Gastroenterology 
 World Journal of Gastroenterology 
 World Journal of Pharmaceutical Research 
 The IOWA Drug Information System (IDIS) which is available with 
Department of Pharmacy Practice was used to collect and collate the literatures 
pertaining to the study. Databases such as Micromedex, Science Direct, NIH 
Medscape, PubMed and NCBI were also widely used. Some textbooks used were: 
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 Clinical Pharmacy and Therapeutics by Roger Walker and Cate 
Whittlesea, 5th Edition, 2012 
 Pharmacotherapy – A Pathophysiologic Approach by Joseph T Dipiro,  
7th Edition, 2008 
 Harrison’s Principles of Internal Medicine, 16th Edition, 2005 
 Essentials of Medical Pharmacology by K D Tripathi, 6th Edition, 2010 
 
PATIENT SELECTION 
Inclusion criteria  
 Patients above 18 years old 
 Patients prescribed with oral or intravenous PPI 
 Patients willing to participate in the study 
Exclusion criteria 
 Patients not willing to participate in the study 
 Patients with insufficient data in their records 
PATIENT INFORMATION FORM 
 A patient information form was prepared to inform the patient or the care 
givers about the purpose and necessity of the study. The patients were assured that 
the confidentiality will be strictly maintained. The model of the information form 
is given in Annexure 2 for reference. 
PATIENT CONSENT FORM 
A patient consent form was prepared and written consent was obtained 
from the patient or the care givers. The model of the consent form is given in 
Annexure 3 for reference. 
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DATA ENTRY FORMAT 
A specially designed data entry format was prepared and used to record the 
patient details, laboratory investigations and diagnosis. The data entry format 
included drug chart, cost comparison table, a table for assessment of 
appropriateness and drug interaction chart. The same is given in Annexure 4 for 
reference. 
METHOD 
Regular ward rounds were carried out in all the wards of the General 
Medicine department. Each patient’s medication profile was reviewed. Patients 
who qualified the inclusion criteria were briefed on the study with the help of the 
patient information form and if anyone was willing to participate in the study, the 
consent was obtained. The data from the medical chart were recorded in 
customized data entry form. The data was analysed to evaluate the appropriateness 
and to compare the cost of prescription. The FDA approved guidelines was used 
to assess the appropriateness in prescription of PPIs. 
REPORT SUBMISSION    
The report of the study after analysis of data was prepared and submitted 
to the study department for necessary modification in future therapy for safe and 
effective treatment. 
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RESULTS AND DISCUSSION 
 
The proposed work entitled “Study on appropriateness and cost 
comparison of prescription of proton pump inhibitors in a tertiary care 
hospital” was a prospective observational study carried out in a 750 bedded 
multispecialty private corporate hospital. A total of 209 patients who met the 
inclusion criteria were included in the study.   
 
GENDER CATEGORIZATION 
  
 The gender categorization of the study population reveals 117 (55.98%) 
were males and 92 (44.02%) were females [Table 2]. The study result reveals that 
there is not much difference in prescription pattern of PPIs between males and 
females. A similar study conducted by Afif et al (2007)45 reported 61% of the 
study population were males and 39 % were females. 
 
AGE CATEGORIZATION 
  
 The age categorization was analysed. Majority of patients, i.e.,  
84 (40.19%) were in the age group >60 years, followed by 76 (36.36%) in the age 
group 41 – 60 years, 38 (18.19%) in the age group 21 – 40 years and the least 
number of patients 11 (5.26%) were in the age group below 20 years [Table 3]. 
The result reveals more number of PPIs were prescribed to patients above 40 
years. A similar study was conducted by Blesson M et al (2015)20 which reported 
that 42.16% comprised of patients in the age group of  60-80 years and 38.12% 
patients were in the age group of 40-60 years.  
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RISK FACTORS ASSOCIATED WITH USE OF PPIs 
 The patients were categorised based on the risk factors associated with use 
of PPIs. The results show that 78 patients (37.32%) were smokers, 48 patients 
(22.96%) were elderly, 43 patients (20.57%) were having stress related profession, 
30 patients (14.35%) were chronic NSAID users and 29 patients (13.88%) were 
alcoholics [Table 4]. 
   
 The study population was categorised under different risk groups based on 
the number of risks. The different risks in the study population was found to be 
age, stress related profession, use of alcohol, smoking and chronic NSAID users. 
The patients were categorised into 4 main groups, i.e. no risk, moderate risk, high 
risk and very high risk categories. Majority of the patients 83 (39.71%) came 
under the moderate risk category, followed by 64 patients (30.62%) in the low risk 
category, 52 patients (24.88%) in the high risk category and 10 patients (4.79%) in 
the very high risk categories [Table 5]. 
 
COMORBID DISEASE CONDITIONS  
 The comorbidities of the study population were analysed. The major 
comorbid condition found is DM [60 patients (28.71%)], followed by SHT in  
51 (24.40%), Cardiac disorders in 24 (11.48%), Renal failure in 21 (10.05%), 
Respiratory infections in 18 (8.61%), Viral fever in 13 (6.22%) and others  
[Table 6]. Among the comorbid conditions observed DM, SHT, UTI, TB and 
anaemia are found to be major associated diseases where multiple drug therapy is 
involved which necessitates prophylactic use of PPI.  
 
DURATION OF HOSPITAL STAY 
 The study population was analysed for the number of days of stay at the 
hospital and majority of patients 89 (42.57%) were admitted at the hospital for 3-5 
days, followed by 66 patients (31.57%) were admitted for 5-7 days, 35 patients 
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(16.77%) were admitted for more than 7 days and 19 patients (9.09%) were 
admitted for lesser than 3 days [Table 7]. The number of increment in hospital 
stay indirectly involves with high cost associated with PPI use, because if IV line 
are available the PPIs are prescribed as parenteral which is higher compared to 
tablets.   
 
DRUGS PRESCRIBED 
 
The total number of drugs prescribed for the study population was found to 
be 2024. A total of 285 (14.08%) antibiotics were prescribed, followed by  
209 (10.33%) PPIs, 155 (7.65%) anti-diabetics, 132 (6.32%) anti-hypertensives, 
129 (6.18%) NSAIDs, 115 (5.51%) anti-emetics, 97 (4.65%) vitamin 
supplements, 81 (3.88%) intravenous fluids, 79 (3.78%) anti-platelets and anti-
coagulants, 75 (3.59%) hypolipidemics and other agents [Table 8]. From the 
results it is observed that antibiotics are the most concomitantly prescribed with 
PPIs in the study population. Krishna K J et al (2016)19 similarly reported more 
percentage of antibiotics (28.25%) used concomitantly with PPIs. It is observed 
that as the number of drugs prescribed increases there is more chance for 
prescribing PPI for prophylactic prevention of PUD or gastric irritation. 
 
CATEGORIZATION OF PPIs PRESCRIBED  
  
Among the 209 PPIs prescribed in the study population pantoprazole was 
the most frequently prescribed 144 (68.89%). Esomeprazole 46 (22.01%) comes 
next in line followed by rabeprazole 17 (8.13%) and omeprazole 2 (0.95%)  
[Table 9]. The result reveals that pantoprazole is the most frequently prescribed 
PPI in the study site and omeprazole is the least prescribed PPI. A similar study 
was conducted by Anton P et al (2016)18 in which 82% patients were prescribed 
pantoprazole. A study by Jungnickel P W (2000)46 stated that pantoprazole has 
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low potential for drug interactions compared to other PPIs. Thus prescribing 
pantoprazole more is found to be beneficial, which avoids risk of drug 
interactions.  
 
DOSAGE FORMS OF PPIs PRESCRIBED 
 
 PPIs are available in the form of tablets and injections. In the study 
population both the tablets as well as parenteral PPIs were prescribed. Majority of 
patients, i.e., 92 (44.02%) were prescribed a combination of both parenteral and 
tablet dosage forms of PPIs. There were 68 (32.54%) patients prescribed tablets 
alone and 49 (23.44%) patients were prescribed parenteral alone [Table 10]. The 
similar result was observed in a study carried out by Shobha C et al (2014)24 
which reported that parenteral use of PPI was less. The use of tablet dosage form 
is recommended in studies which report that tablets are cost effective than 
parenteral preparations. The assessment of effectiveness and obstacles of taking 
tablet by the patient can be done before prescribing PPIs which in turn will reduce 
the cost of therapy. 
 
DOSING FREQUENCY OF PPIs PRESCRIBED 
  
 Assessment of dosing frequency of PPIs prescribed revealed that in 95 
prescriptions twice daily dosing of pantoprazole was prescribed and in 49 
prescriptions once daily dosing of pantoprazole was prescribed. In the case of 
esomeprazole twice daily dosing was prescribed in 30 prescriptions, once daily 
dosing of esomeprazole was prescribed in 15 prescriptions and one patient was 
prescribed three times a day dose of esomeprazole. Once daily dosing of 
rabeprazole was prescribed in 8 prescriptions and twice daily rabeprazole was 
prescribed in 9 prescriptions. Omeprazole was prescribed as twice daily in 2 
prescriptions [Table 11]. As per FDA guidelines [Table 1] twice daily dosing of 
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pantoprazole is inappropriate, once daily dosing is sufficient to produce desired 
effects. Thus, twice daily dosing of pantoprazole in the study department was 
changed to once daily dosing by making necessary intervention with physician.  
 
EVALUATION OF APPROPRIATENESS IN USE OF PPIs 
 
 Appropriateness of prescription of PPIs in the study population was 
analysed using the FDA guidelines [Table 1], out of 209 patients 115 (55.02%) 
were found to be appropriately prescribed with PPIs, which indicates there is 
recommended conditions as mentioned in guidelines and 94 (44.98%) 
prescriptions were found to be inappropriate, i.e., there was no necessary 
indication of PPI use as per the guidelines [Table 12]. Similar results were found 
out by Blesson M et al (2015)20, which reported that 60.41% patients had 
appropriate prescription of PPI and 39.58% patients had inappropriate prescription 
of PPIs. 
   
 Among the prescription with appropriate use of PPIs the indications were 
analysed and it revealed that PPIs were utilised for the prophylactic indication in 
53 (46.08%) patients where polypharmacy was there in their prescription, 
followed by 44 (38.26%) prescription had NSAIDs and 9 cases (7.83%) diagnosed 
with AGE. The PPIs were prescribed very less in case of PUD. The result reveals 
that 4 patients (3.48%) diagnosed with gastritis were prescribed with PPI followed 
by 3 patients (2.61%) with duodenal ulcer and 2 patients (1.74%) suffering from 
APD were prescribed with PPIs [Table 13]. Thus the results reveal that more 
number of patients was prescribed with PPIs for the prevention of ulcer rather 
than treating ulcer. This result was supported by a study carried out by Nousheen 
et al (2014)23 in which 58% patients received PPIs for the prophylactic 
indications. Thus the prophylactic use of PPIs can be evaluated and if alternatives 
are available that can be utilised in order to lower the risk involved with PPI use. 
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 The inappropriate prescriptions with PPIs were analysed and it was found 
that inappropriateness in prescriptions may be due to several reasons, i.e. wrong 
frequency, wrong dosage form, availability of alternative, prolonged duration of 
treatment, inappropriate indication and occurrence of adverse events. Majority of 
the inappropriate prescriptions involved pantoprazole followed by esomeprazole 
and rabeprazole [Table 14]. The inappropriateness identified were documented 
and the management measures were taken to prevent inappropriate prescription 
through proper intervention 
 
COST COMPARISON 
 
 A wide variety of PPIs are available in the study site and the cost of each 
PPI also varies. Analysis of the cost of different parenteral PPIs, oral PPIs and 
H2RAs available was carried out. The result of cost comparison showed that 
among IV PPIs injection Esomac (Esomeprazole) was the most costly (Rs. 92.5) 
and injection Pantocid (Pantoprazole) was the least costly (Rs. 43.38) drug. 
Among oral PPIs tablet Pantocid L (Pantoprazole) was the most costly (Rs. 18.12) 
and tablet Omez (Omeprazole) was the least costly (Rs. 3.49). The cost of H2RAs 
were also analysed and it is found that the H2RAs are cheaper than PPIs. 
Wherever possible the use of H2RAs is recommended instead of the more costly 
PPIs. The cost of treatment can be reduced in 94 patients who have been 
prescribed with PPIs inappropriately [Table 15]. Among these 94 patients, 71 
patients were identified with H2RAs as an alternate drug instead of PPI by which 
the cost of treatment will be reduced. An unnecessary healthcare cost to the 
patient is a matter of concern and necessary action must be taken. The possibility 
of alternate and reducing the cost of treatment was reported to the study 
department and immediate interventions were implicated.  
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DRUG INTERACTIONS 
 
 Drug interactions associated with PPIs were analysed. A total of 157 drug 
interactions were identified which consisted of 3 major interactions, 153 moderate 
interactions and 1 minor interaction [Table 16]. Out of 157, 21 different types of 
interactions associated with PPIs were identified of which the most common 
interaction was that of clopidogrel and pantoprazole, followed by atorvastatin and 
pantoprazole and others.  
 
 From the results it can be observed that a high degree of appropriateness is 
seen in use of PPIs in the study department. The possible reason of 
inappropriateness were identified and reported to the study department. The 
results signified the importance of the role of the clinical pharmacist in monitoring 
the prescriptions with PPIs. The study also warrants the need for developing 
guidelines for PPI use. Even though there are no major risks seen in study 
population by the use of PPI but rational prescribing of PPI will reduce overall 
cost of therapy as well as improves the patient safety. 
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Table 2: Distribution of Patients Based on Gender (N=209) 
Sl. No. Gender Number (N) Percentage (%) 
1.  Male 117 55.98 
2.  Female 92 44.02 
 
 
 
 
 
 
 
 
 
Males, 55.98%
Females, 
44.02%
Figure 1: Gender (N=209)
Males Females
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Table 3: Distribution of Patients Based on Age (N=209) 
 
Sl. No. Age Number (N) Percentage (%) 
1.  Less than 20 years 11 5.26 
2.  21 – 40 years 38 18.19 
3.  41 – 60 years 76 36.36 
4.  More than 60 years 84 40.19 
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Table 4: Risk Factors associated with use of PPIs (N=209) 
Sl. No. Risk Factors Number (N) Percentage (%) 
1.  Age 48 22.96 
2.  Alcoholic 29 13.88 
3.  Smoker 78 37.32 
4.  Stress 43 20.57 
5.  Chronic use of NSAIDs 30 14.35 
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Table 5: Risk Categorization (N=209) 
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Figure 4: Risk Categorization
Sl. No. Risk Categories Number (N) Percentage (%) 
1.  
No Risk 
(no risk factors) 
64 30.62 
2.  
Moderate Risk 
(1 risk factor) 
83 39.71 
3.  
High Risk 
(2 risk factors) 
52 24.88 
4.  
Very High Risk 
(more than 2 risk factors) 
10 4.79 
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Table 6: Comorbid Disease Conditions (N=209) 
 
Sl. No. Comorbid Conditions Number (N) Percentage (%) 
1.  DM 60 28.71 
2.  SHT 51 24.40 
3.  Cardiac Disorders 24 11.48 
4.  Renal Failure 21 10.05 
5.  Respiratory Infections 18 8.61 
6.  Viral Fever 13 6.22 
7.  Stroke 13 6.22 
8.  Anaemia 12 5.74 
9.  Seizure 10 4.78 
10. UTI 10 4.78 
11. CVA 8 3.83 
12. TB 5 2.39 
13. COPD 4 1.91 
14. Diabetic Ketoacidosis 3 1.44 
15. Malaria 3 1.44 
16. Hypothyroidism 3 1.44 
17. Cirrhosis 2 0.96 
18. Jaundice 2 0.96 
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Table 7: Duration of Hospital Stay (N=209) 
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Sl. No. Duration of Stay Number (N) Percentage (%) 
1.  Lesser than 3 days 19 9.09 
2.  3 – 5 days 89 42.57 
3.  5 – 7 days 66 31.57 
4.  More than 7 days 35 16.77 
Results & Discussion 
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Table 8: Drugs prescribed (N=2024) 
Sl. No. Drug Class Number (N) Percentage (%) 
1.  Antibiotics 285 14.08 
2.  PPIs 209 10.33 
3.  Anti-diabetics 155 7.65 
4.  Anti-hypertensives 132 6.32 
5.  NSAIDs 129 6.18 
6.  Anti-emetics 115 5.51 
7.  Vitamin supplements 97 4.65 
8.  Intravenous fluids 81 3.88 
9.  
Antiplatelets and 
Anticoagulants 79 3.78 
10.  Hypolipidemics 75 3.59 
11.  Probiotics 74 3.55 
12.  Calcium supplements 69 3.31 
13.  Antiepileptics 58 2.77 
14.  Bronchodilators 45 2.16 
15.  Sedatives 44 2.11 
16.  Diuretics 41 1.96 
17.  Antacids 31 1.48 
18.  Laxatives 25 1.19 
19.  Cardiovascular agents 25 1.19 
20.  Protein supplements 24 1.15 
21.  Corticosteroids 22 1.05 
22.  Antidiarrhoeals 17 0.81 
23.  Opioids 14 0.67 
24.  Anti-gout agents 13 0.62 
25.  Liver protectives 12 0.57 
26.  Anti-tussives 11 0.53 
27.  Anti TB agents 10 0.47 
28.  Iron supplements 8 0.38 
29.  Antimalarials 6 0.28 
30.  Others 118 5.65 
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Table 9: PPIs Prescribed (N=209) 
Sl. No. PPIs Number (N) Percentage (%) 
1.  Pantoprazole 144 68.89 
2.  Esomeprazole 46 22.01 
3.  Rabeprazole 17 8.13 
4.  Omeprazole 2 0.95 
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Table 10: Distribution of Dosage forms of PPIs prescribed (N=209) 
 
Sl. No. Dosage Form Number (N) Percentage (%) 
1.  
IV 49 23.44 
2.  
Oral 68 32.54 
3.  
Combination 92 44.02 
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Table 11: Dosing Frequency of PPIs Prescribed (N=209) 
 
 
 
 
 
49
95
15
30
1
8 9
2
0
10
20
30
40
50
60
70
80
90
100
110
O.D B.D T.I.D
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Sl. No. PPIs Prescribed 
Frequency 
O.D B.D T.I.D 
1.  Pantoprazole 49 95 - 
2.  Esomeprazole 15 30 1 
3.  Rabeprazole 8 9 - 
4.  Omeprazole - 2 - 
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Table 12: Evaluation of Appropriateness (N=209) 
Sl. No. Appropriateness Number (N) Percentage (%) 
1.  Appropriate 115 55.02 
2.  Inappropriate 94 44.98 
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Figure 9: Evaluation of Appropriateness 
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Table 13: Categorization of Appropriate Indications of PPI use (N=115) 
Sl. No. Indications Number (N) Percentage (%) 
Ulcer Related Events 
1.  Gastritis 4 3.48 
2.  Duodenal Ulcer 3 2.61 
3.  APD 2 1.74 
Prophylactic Indications for the use of PPIs 
4.  NSAIDs 44 38.26 
5.  Polypharmacy 53 46.08 
6.  AGE 9 7.83 
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Table 14: Categorization of Inappropriate Use of PPIs 
 
 
Sl. 
No. 
PPIs involved in 
Inappropriate 
Prescribing 
Inappropriateness Identified 
Number 
(N) 
1.  Pantoprazole 
1. Wrong Frequency 
2. Wrong Dosage Form 
3. Availability of Alternative 
4. Prolonged Duration of Treatment 
5. Inappropriate Indication 
6. Occurrence of Adverse Event 
23 
10 
42 
31 
22 
14 
2.  Esomeprazole 
1. Wrong Dosage Form 
2. Availability of Alternative 
3. Inappropriate Indication 
4. Prolonged Duration of 
 Treatment 
5. Occurrence of Adverse Event 
4 
16 
8 
11 
11 
3.  Rabeprazole 
1. Availability of Alternative 
2. Inappropriate Indication 
3. Occurrence of Adverse Event 
13 
11 
9 
Results & Discussion 
 
 
Study On Appropriateness And Cost Comparison Of  Prescription  
Of Proton Pump Inhibitors In A Tertiary Care Hospital 46 
Table 15: Cost Comparison of PPIs Prescribed  
S.No. Prescribed 
PPI 
Cost/Unit 
(in Rs.) 
Recommended 
alternative 
Cost/Unit 
(in Rs.) 
No. of 
patients  
1 Inj. Esomac 92.5 Inj. Aciloc 3.29 16 
2 Inj. Pantocid 43.38 T. Zinetac 1.34 14 
3 Inj. Pan  56.61 Inj. Rantac 13.35 13 
4 Inj. Happi 65 Inj. Aciloc 3.29 13 
5 T. Pantocid 7.9 T. Histac 1.22 9 
6 Inj. Pan 56.61 T. Pan 7.7 8 
7 Inj. Esomac 92.5 Inj. Raciper 49 7 
8 T. Pantodac 9.55 T. Rantac 0.72 6 
9 Inj. Raciper 49 T. Neksium 9.90 4 
10 Inj. Pantocid 43.38 T. Pantodac 9.55 4 
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Table 16: Drug Interactions (N=157)  
S.No. 
Interacting 
Drugs 
Interaction Severity Number 
1 
Clopidogrel + 
Esomeprazole 
May reduce cardio-protective 
effect of clopidogrel 
Major 3 
2 
Clopidogrel + 
Pantoprazole 
May reduce cardio-protective 
effect of clopidogrel 
Moderate 34 
3 
Atorvastatin + 
Pantoprazole 
May increase plasma 
concentration of atorvastatin 
and increase risk of myopathy 
Moderate 31 
4 
Aspirin + 
Pantoprazole 
May decrease oral 
bioavailability of aspirin 
Moderate 26 
5 
Torsemide +  
Pantoprazole 
May increase risk of 
hypomagnesemia 
Moderate 10 
6 
Furosemide + 
Pantoprazole 
May increase risk of 
hypomagnesemia 
Moderate 8 
7 
Amikacin + 
Esomeprazole 
May increase risk of 
hypomagnesemia 
Moderate 8 
8 
Cefpodoxime + 
Esomeprazole 
Oral bioavailability of 
cefpodoxime may be reduced 
Moderate 7 
9 
Digoxin + 
Pantoprazole 
May increase blood levels of 
digoxin and increase its effects 
Moderate 6 
10 
Amikacin + 
Pantoprazole 
May increase risk of 
hypomagnesemia 
Moderate 5 
11 
Oxcarbazepine + 
Pantoprazole 
May increase plasma 
concentration of pantoprazole 
Moderate 5 
12 
Cefpodoxime + 
Pantoprazole 
Oral bioavailability of 
cefpodoxime may be reduced 
Moderate 2 
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S.No. 
Interacting 
Drugs 
Interaction Severity Number 
13 
Ferrous fumarate 
+ Pantoprazole 
Absorption of iron may be 
impaired 
Moderate 2 
14 
Iron + 
Esomeprazole 
Absorption of iron may be 
impaired 
Moderate 2 
15 
Rifampicin + 
Esomeprazole 
May decrease plasma 
concentration of 
esomeprazole 
Moderate 2 
16 
Phenytoin + 
Esomeprazole 
May increase plasma 
concentration of phenytoin 
Moderate 1 
17 
Theophylline + 
Esomeprazole 
Rate of absorption of 
theophylline may be 
increased 
Moderate 1 
18 
Theophylline + 
Pantoprazole 
Rate of absorption of 
theophylline may be 
increased 
Moderate 1 
19 
Torsemide + 
Rabeprazole 
May increase risk of 
hypomagnesemia 
Moderate 1 
20 
Warfarin + 
Pantoprazole 
May increase INR and 
prothrombin time 
Moderate 1 
21 
Aspirin + 
Rabeprazole 
Oral bioavailability of 
aspirin may be decreased 
Minor 1 
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CONCLUSION 
The study on appropriateness and cost comparison of prescription of PPIs 
was successfully carried out. Most of the PPI prescriptions are found to be 
appropriate at the study site. The interventions made by the pharmacist avoided 
the inappropriate use of PPI at the study site. Most of the inappropriate 
prescriptions were consisting increased frequency of dosing and utilising PPIs for 
prophylactic use. Reducing PPI use will prevent the risk associated with PPIs and 
also reduce cost involved with its use. 
 To conclude, the present study suggests that physician and clinical 
pharmacist should work together to increase appropriate use of PPIs. The 
inappropriate use of PPIs must be prevented through proper interventions. The 
development of guidelines for PPI usage will avoid irrational prescription of PPIs 
and reduce cost of therapy. The need for PPI use in the individual patient must be 
evaluated by the pharmacist and if any possible alternatives are found to be 
effective the same can be reported to the physician. 
 The appropriate use of PPIs will ensure the patient safety by reducing the 
risks associated with unnecessary prescription of PPIs. The regular monitoring of 
prescription of PPI by clinical pharmacist is the need of the hour.  
Future Outlook 
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FUTURE OUTLOOK 
The present study reveals some extent of inappropriate use of PPIs. There 
is no established Indian guideline regarding the use of PPIs. Hence in future it is 
necessary to prepare institutional guideline for the use of PPI and evaluation can 
be done based on the new implemented guideline in different setup. The impact 
and risk involved with overuse of PPI has not been thoroughly revealed, so studies 
which focus on the impact of chronic use of PPIs are necessary to determine the 
risk associated with long term usage of PPIs. 
 The comparative studies on PPIs and alternatives will be useful to reduce 
the use of PPIs and thereby reduce the risk as well as cost. The future 
pharmacoeconomical analysis of PPIs will be useful to decide the PPI use in 
patient with poor economy.  
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